期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 71, 期 10, 页码 1063-1074出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.12.060
关键词
atrial fibrillation; digoxin; heart failure; mortality
资金
- Bristol-Myers Squibb
- Pfizer
- Agency for Healthcare Research and Quality (AHRQ) [R03 HS24310]
- GlaxoSmithKline
- Medtronic
- Bayer
- Boehringer Ingelheim
- Daiichi-Sankyo
- Merck Co.
- Portola
- St. Jude Medical
- Amgen
- Merck
- Sigma-Tau
- AstraZeneca
- Sanofi
- Bristol-Myers Squibb/ Pfizer
- Bristol-Myers Squibb/Pfizer
- Johnson Johnson
- Abbott
- CSL Behring
- Tenax Therapeutics
- Cempra
- CryoLife
- Portola Pharmaceuticals
- Vaso-Prep Surgical
- Armetheon
- Janssen Pharmaceuticals
- Medtronic Foundation
- Novartis Corporation
- Medicines Company
- Gilead Sciences, Inc.
- Hoffmann-La Roche
- Janssen
- Medtronic Inc.
- Novartis
- Verseon
- Roche Diagnostics
- AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS024310] Funding Source: NIH RePORTER
BACKGROUND Digoxin is widely used in patients with atrial fibrillation (AF). OBJECTIVES The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and if the association was modified by heart failure and/or serum digoxin concentration. METHODS The association between digoxin use and mortality was assessed in 17,897 patients by using a propensity score-adjusted analysis and in new digoxin users during the trial versus propensity score-matched control participants. The authors investigated the independent association between serum digoxin concentration and mortality after multivariable adjustment. RESULTS At baseline, 5,824 (32.5%) patients were receiving digoxin. Baseline digoxin use was not associated with an increased risk of death (adjusted hazard ratio [HR]: 1.09; 95% confidence interval [CI]: 0.96 to 1.23; p = 0.19). However, patients with a serum digoxin concentration $ 1.2 ng/ml had a 56% increased hazard of mortality (adjusted HR: 1.56; 95% CI: 1.20 to 2.04) compared with those not on digoxin. When analyzed as a continuous variable, serum digoxin concentration was associated with a 19% higher adjusted hazard of death for each 0.5-ng/ml increase (p = 0.0010); these results were similar for patients with and without heart failure. Compared with propensity score-matched control participants, the risk of death (adjusted HR: 1.78; 95% CI: 1.37 to 2.31) and sudden death (adjusted HR: 2.14; 95% CI: 1.11 to 4.12) was significantly higher in new digoxin users. CONCLUSIONS In patients with AF taking digoxin, the risk of death was independently related to serum digoxin concentration and was highest in patients with concentrations $ 1.2 ng/ml. Initiating digoxin was independently associated with higher mortality in patients with AF, regardless of heart failure. (c) 2018 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据